The manuscript was made by a medical writer who was an employee of the sponsor, with insight from all the authors. The first author made a decision to submit the manuscript for publication. We determined that a sample of 200 patients in each treatment group would supply the study with more than 90 percent capacity to detect an improvement of at least 30 %age factors in the price of sustained virologic response, in comparison with a calculated control rate of 60 percent. This 60 percent rate was based on rates of sustained virologic response in phase 3 trials of telaprevir13 and boceprevir,14 enabling a rate of sustained virologic response that was 5 %age points less than the adjusted rate of 65 percent, in trade for an anticipated improved safety profile and shorter period of treatment.Aureus ; 27 of the 217 isolates were clindamycin-resistant, and 1 of 217 isolates at the test-of-treatment visit was 80.3 percent in the clindamycin group and 77.7 percent . In the population that may be evaluated , the rate of treatment was 89.5 percent in the clindamycin group and 88.2 percent . There were no significant variations between treatment groupings, in either the intention-to-treat population or the population that could be evaluated, in subgroups consisting of children, adults, or individuals with cellulitis, abscesses, or blended abscess and cellulitis lesions . In addition, there were no significant between-group distinctions in subgroups of individuals infected with S. Aureus, MRSA, or MSSA in either the intention-to-treat populace or the populace that could be evaluated.